1748-P: IGlarLixi Improves PPG and DTIR in Asian People with T2D (PwT2D): Post Hoc Pooled Analysis of Ph3 Studies

by sugaradmin



Introduction and Objective: Ph3 studies have compared iGlarLixi vs individual components (LixiLan-O-AP, LixiLan-L-CN) or IDegAsp (SoliD) in Asian PwT2D. This pooled analysis investigated the effect of iGlarLixi on PPG and SMPG derived time in range (dTIR).Methods: Changes in SMPG profile were analyzed in the pooled iGlarLixi vs control arms of LixiLan-O-AP, LixiLan-L-CN and SoliD.Results: Baseline characteristics are shown in Table 1. At EOT, iGlarLixi was associated with consistently greater reductions vs controls in the 7-point SMPG profile, except for pre-breakfast SMPG (Figure 1). LSM change in average 7-point, 2h PPG and dTIR was also greater with iGlarLixi vs comparators (Table 1). The % time of SMPG in range was higher with iGlarLixi vs controls.Conclusion: This analysis showed consistent PPG and dTIR benefits over 24h with iGlarLixi vs comparators in Asian people with T2D.

Disclosure

W. Lin: None. Q. Xu: None. H. Li: None. A. Alvarez: Employee; Current; Sanofi. F. Lauand: Employee; Current; Sanofi. L. Melas-Melt: None. L. Kang: Employee; Current; Sanofi China. Q. Du: Employee; Current; Sanofi China. X. Wang: Employee; Current; Sanofi China. H. Kuang: None.

Funding

These studies were funded by Sanofi (ClinicalTrials.gov identifiers: NCT03798054, NCT03798080, and NCT05413369). Professional medical writing support was provided by Sarah Greig, PhD, CMPP, of Springer Health+, and was funded by Sanofi.



Source link